Assessment of ICP in Idiopathic Intracranial Hypertension Using Transocular Ultrasound and Transcranial Doppler

Sponsor
Danish Headache Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT04314128
Collaborator
(none)
75
1
1
111
0.7

Study Details

Study Description

Brief Summary

Idiopathic Intracranial Hypertension (IIH) is a rare disease, primarily affecting overweight females of child-bearing age. Patients suffer from increased intracranial pressure (ICP), typically resulting in headaches, visual disturbances and bilateral papilledema, pulsatile tinnitus and cognitive deficits. The disease is difficult to diagnose, treat and monitor. The only current method of measuring the ICP in day-to-day clinical practice is by lumbar puncture. This procedure is invasive, and often painful for the patient. There is an unmet need of methods that can reliable measure or estimate ICP in a non-invasive manner. Ultrasound is one such potential method, and the aim of this study is to investigate the use of ocular ultrasound and transcranial doppler to measure or estimate ICP.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: TOS and TCD
N/A

Detailed Description

This study is a prospective cohort study. Investigators plan to include 50 patients in whom the IIH-diagnosis is suspected. Patients are referred from general practitioners, neurologists or ophthalmologists to the Danish Headache Center or admitted to the Neurology ward when the IIH diagnosis is suspected.

As part of an established routine clinical work-up to establish the diagnosis of IIH, all patients will undergo (according to the Friedman criteria) the following examinations:

A)

  1. An interview (history taking) and clinical examination

  2. Routine laboratory tests (blood tests)

  3. Ophthalmological examination

  4. Lumbar puncture with measurement of the ICP

  5. Magnetic resonance imaging (MRI) of the brain

Additionally the following investigations will be performed at baseline (before and after lumbar puncture):

  1. Transorbital sonography (TOS) C) Transcranial Doppler When the patient is seen at the clinic for their regular follow-up visits the same measurements will be done.

A control group of healthy participants (NR=25) will be included in whom TOS (B) and TCD (C) will be performed in order to compare the values between the patient group (IIH) and control group. Controls will be included to match the patients according to BMI, age and gender.

All ultrasound images- and films will be saved, and evaluated by a blinded investigator.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
75 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Single group, prospective cohort study with healthy controls.Single group, prospective cohort study with healthy controls.
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Assessment of Raised Intracranial Pressure in Patients With Idiopathic Intracranial Hypertension by Optic Nerve Sheath Diameter and Transcranial Doppler Measurements
Actual Study Start Date :
Jan 1, 2020
Anticipated Primary Completion Date :
Apr 1, 2029
Anticipated Study Completion Date :
Apr 1, 2029

Arms and Interventions

Arm Intervention/Treatment
Other: Patients suspected of IIH at baseline

Intervention: TOS and TCD measurements at baseline, and at routine follow-ups. Healthy controls will be recruited to match the patients.

Diagnostic Test: TOS and TCD
TOS: Transorbital sonography TCD: Transcranial Doppler

Outcome Measures

Primary Outcome Measures

  1. Correlation between opening pressure and ONSD [1 year]

    Optic nerve sheath diameter (ONSD) potential correlation with opening pressure.

  2. Correlaton between opening pressure and ONSD/ETD ratio [1 year]

    ONSD/ETD (external transverse diameter) ratio and potential correlation with opening pressure.

  3. Comparison of ONSD in IIH and healthy controls [1 year]

    Comparison of ONSD in patients with elevated ICP (IIH) and healthy controls, age- sex and BMI matched.

Secondary Outcome Measures

  1. Optic disc elevation [1 year]

    Optic disc elevation measured by ultrasound in IIH compared with healthy controls

  2. ONSD diameter on MR c in patients with IIH [1 year]

    ONSD and correlation with ONSD on orbital MRI.

  3. Changes in the optic nerve (ONSD) [1 month]

    Changes in ONSD after 1 month

  4. Changes in the optic nerve (ONSD) [6 months]

    Changes in ONSD after 6 months

  5. Changes in the optic nerve (ODE) [1 month]

    Changes in ODE (optic disc elevation) after 1 month

  6. Changes in the optic nerve (ODE) [6 months]

    Changes in ODE(optic disc elevation) after 6 months

  7. TCD (PI - pulsatility index) in patients with IIH [2 years]

    Evaluation of pulsatility index for major intracranial arteries (PI) using doppler ultrasound in patients with raised intracranial pressure (IIH) compared with normal values.

  8. TCD (MBFV - mean blood flow velocity) in patients with IIH [2 years]

    Evaluation of mean blood flow velocity (MBFV) for major intracranial arteries using doppler ultrasound in patients with raised intracranial pressure (IIH) compared with normal values.

  9. TCD (RI - resistance index) in patients with IIH [2 years]

    Evaluation of resistance index (RI) for major intracranial arteries using doppler ultrasound in patients with raised intracranial pressure (IIH) compared with normal values.

  10. Neuro-ophthalmological evaluation of papilledema versus ultrasound evaluation of the optic nerve [2 years]

    Papilledema and the optic nerve is usually evaluated by neuro-ophthalmologists in patients with IIH. Investigators will compare this evaluation with the assessment made by TOS ultrasound.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
PATIENT GROUP (ARM 1):
Inclusion Criteria:
  • Age 18-65

  • Patients in whom the IIH diagnosis is suspected/or confirmed

  • The diagnosis of migraine with or without aura or tension-type headache is allowed as a comorbid headache type.

  • Participants must read and understand the Danish language, or have an official interpreter present to be able to understand the work-up and sign the participation consent for the study

Exclusion Criteria:
  • Pregnant or breastfeeding females

  • Patients who do not need a diagnostic lumbar puncture at the time of evaluation

  • Patients treated with acetazolamide, topiramate or furosemide for IIH or suspected IIH before inclusion in the study (baseline)

  • Any other primary or secondary headache diagnosis than migraine with or without aura or tension type headache as a comorbid disorder

  • Patients in whom the examination cannot be performed due to anatomical reasons such as severe head dysmorphia or severe ophthalmological diseases

  • Participants with secondary causes of raised intracranial pressure, or patients that have been treated for such (e.g. brain tumor, hydrocephalus, stroke or severe head injury)

  • Participants with known atherosclerotic disease or known heart disease

CONTROL GROUP (ARM 2):
Inclusion criteria:
  • Age 18-65

  • Healthy persons who do not suffer from any form of primary headache except infrequent tension-type headache

  • Participants must read and understand the Danish language or have an official interpreter present to be able to sign the participation consent for the study.

Exclusion criteria:
  • Pregnant or breastfeeding females

  • Participants in whom the examination cannot be performed due to anatomical reasons such as severe head dysmorphia or severe ophthalmological diseases

Contacts and Locations

Locations

Site City State Country Postal Code
1 Danish Headache Center Glostrup Region Hovedstaden Denmark 2600

Sponsors and Collaborators

  • Danish Headache Center

Investigators

  • Principal Investigator: Rigmor Jensen, Dr.med., Danish Headache Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Johanne Severinsen, Medical Doctor, Danish Headache Center
ClinicalTrials.gov Identifier:
NCT04314128
Other Study ID Numbers:
  • H-19029542
First Posted:
Mar 19, 2020
Last Update Posted:
Feb 2, 2021
Last Verified:
Feb 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 2, 2021